375
Participants
Start Date
December 8, 2020
Primary Completion Date
August 23, 2022
Study Completion Date
August 23, 2022
Semaglutide
Semaglutide administered subcutaneously (s.c., under the skin) as well as diet and physical activity counselling for 44 weeks. Doses gradually increased to 2.4 mg
Placebo (semaglutide)
Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks
Ajou University Hospital, Gyeonggi-do
Chinese People's Liberation Army General Hospital-Endocrinology, Beijing
Beijing Pinggu Hospital-Endocrinology, Beijing
The First Bethune hospital of Jilin University-Endocrinology, Changchun
Huashan Hospital Fudan University-Endocrinology, Shanghai
Shanghai Tenth People's Hospital (Tenth People's of Tongji University)-Endocrinology, Shanghai
Shanghai Fifth People's Hospital-Endocrinology, Shanghai
Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai
Shanghai Pudong New Area People's Hospital-Endocrinology, Shanghai
The Second Affiliated Hospital of Nanjing Medical University-Endocrinology, Nanjing
Jiangsu Province Hospital-Endocrinology, Nanjing
The Affiliated Hospital of Jiangsu University-Endocrinology, Zhenjiang
Changzhou No.2 People's Hospital, Yanghu Branch, Changzhou
The First Affiliated Hospital of Soochow University, Suzhou
Jinan Central Hospital Affiliated to Shandong University, Jinan
General Hospital of Tianjin Medical University-Endocrinology, Tianjin
The Second Hospital of Tianjin Medical University, Tianjin
Fujian Medical University Union Hospital-Endocrinology, Fuzhou
Chongqing University Three Gorges Hospital, Chongqing
The Second Affiliated Hospital of Kunming Medical University, Kunming
Instituto de Ciências Farmacêuticas de Estudos e Pesquisas, Aparecida de Goiânia
CPCLIN - Centro de Pesquisas Clínicas, São Paulo
Cangzhou People's Hospital, Cangzhou
Harrison International Peace Hospital-Endocrinology, Hengshui
The Second Hospital of Hebei Medical University-Endocrinology, Shijiazhuang
Inner Mongolia People's Hospital-Endocrinology, Hohhot
The affiliated Hospital of Inner Mongolia Medical University-Endocrinology, Hohhot
Prince of Wales Hospital, Shatin, New Territories
Seoul National University Hospital, Seoul
Lead Sponsor
Novo Nordisk A/S
INDUSTRY